OncoCyte Co. (NASDAQ:OCX – Get Free Report) Director Andrew Arno bought 33,898 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
OncoCyte Price Performance
Shares of OCX stock opened at $2.59 on Thursday. The firm has a fifty day moving average of $2.95 and a 200-day moving average of $3.06. OncoCyte Co. has a 12-month low of $2.08 and a 12-month high of $6.80.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on the stock. StockNews.com assumed coverage on shares of OncoCyte in a report on Thursday. They issued a “sell” rating on the stock. Stephens reiterated an “equal weight” rating and issued a $4.00 target price on shares of OncoCyte in a report on Wednesday. Finally, Benchmark reissued a “speculative buy” rating and set a $5.00 price objective on shares of OncoCyte in a research report on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.90.
Institutional Investors Weigh In On OncoCyte
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in OncoCyte by 3.2% in the fourth quarter. Vanguard Group Inc. now owns 247,873 shares of the company’s stock valued at $620,000 after purchasing an additional 7,784 shares in the last quarter. DCF Advisers LLC grew its position in OncoCyte by 107.0% in the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after purchasing an additional 13,000 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in OncoCyte in the first quarter valued at $25,000. Goldman Sachs Group Inc. grew its position in OncoCyte by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock valued at $686,000 after purchasing an additional 24,964 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in OncoCyte in the second quarter valued at $25,000. Institutional investors own 55.35% of the company’s stock.
About OncoCyte
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Further Reading
- Five stocks we like better than OncoCyte
- Consumer Staples Stocks, Explained
- United Airlines Soars on Earnings Beat
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.